TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas

Francesca Maddalena1, Valentina Condelli1, Danilo Swann Matassa2, Consiglia Pacelli3, Rosella Scrima3, Giacomo Lettini1, Valeria Li Bergolis4, Michele Pietrafesa1, Fabiana Crispo1, Annamaria Piscazzi4, Giovanni Storto5, Nazzareno Capitanio3, Franca Esposito2 and Matteo Landriscina1,4

1 Laboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
2 Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Italy
3 Department of Clinical and Experimental Medicine, University of Foggia, Italy
4 Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy
5 Nuclear Medicine Unit, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy

Keywords
cetuximab; glycolysis; oxidative phosphorylation; phosphofructokinase 1; TRAP1

Correspondence
M. Landriscina, Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di Foggia, Viale Pinto, 1, Foggia 71100, Italy
Tel: +39 081 7463145
E-mail: franca.esposito@unina.it

Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient-derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and 18F-fluoro-2-deoxy-glucose (18F-FDG) uptake upon PET scan or GLUT1 expression in human CRCs. Consistently, TRAP1 enhances GLUT1 expression, glucose uptake, and lactate production and downregulates OXPHOS in CRC patient-derived spheroids and cell lines. Mechanistically, TRAP1 maximizes lactate production to balance low OXPHOS through the regulation of the glycolytic enzyme phosphofructokinase-1 (PFK1); this depends on the interaction between TRAP1 and PFK1, which favors PFK1 glycolytic activity and prevents its ubiquitination/degradation. By contrast, TRAP1/PFK1 interaction is lost in conditions of enhanced OXPHOS, which results in loss of TRAP1 regulation of PFK1 activity and lactate production. Notably, TRAP1 regulation of glycolysis is involved in resistance of RAS-wild-type CRCs to EGFR monoclonals. Indeed, either TRAP1 upregulation or high glycolytic metabolism impairs cetuximab activity in vitro, whereas TRAP1 targeting and/or inhibition of glycolytic pathway enhances cell response to cetuximab. Finally, a linear correlation between 18F-FDG PET uptake and poor response to cetuximab in first-line therapy in human metastatic CRCs was observed. These results suggest that TRAP1 is a key determinant of resistance to EGFR inhibitors.

Abbreviations
18F-FDG, 18F-fluoro-2-deoxy-glucose; 2-DG, 2-deoxy-glucose; BRAF, v-raf murine sarcoma viral oncogene homolog B; CRC, human colorectal carcinoma; ECAR, extracellular acidification rate; EGFR, epidermal growth factor receptor; GLUT1, glucose transporter member 1; HKII, hexokinase II; HSP90, heat-shock protein 90; MCT4, solute carrier family 16 (monocarboxylic acid transporters), member 3; OCR, oxygen consumption rates; OXPHOS, oxidative phosphorylation; PET, positron emission tomography; PFK1, phosphofructokinase 1; RAS, Kirsten rat sarcoma viral oncogene homolog; SUVmax, maximum standardized uptake value; TRAP1, TNF receptor-associated protein 1.
1. Introduction

Cancer cells adapt their metabolism to extracellular environment to meet the high energetic demand induced by rapid cell proliferation, promote survival, and favor long-term maintenance [1]. In such a context, Warburg metabolism, with glucose being converted to lactate even in the presence of oxygen, is considered a hallmark of cancer [2], due to its relevance in supplying cancer cells with precursors of proteins, lipids, amino acids, and nucleic acids to build cellular structures and maintain high proliferation rates [3]. However, recent evidence suggests that (a) mitochondria still play important roles in bioenergetics in cancer cells [4], (b) specific cancer types are characterized by a prevalent oxidative metabolism [5], and (c) metabolic rewiring from aerobic glycolysis to oxidative phosphorylation (OXPHOS) and vice versa is responsible for driving cancer progression [6]. Intriguingly, it has been suggested that metabolic alterations sustain almost all known hallmarks of cancer and that metabolic pathways may provide very interesting and novel therapeutic targets [7].

In such a context, increasing roles are attributed to molecular chaperones, which are not just multifunctional proteins, but rather molecular hubs connecting different metabolic pathways [8]. The mitochondrial HSP90 chaperone family member, TRAP1, is involved in several functions of cancer cells and, among others, regulation of cell bioenergetics [9–14]. Indeed, the primary TRAP1 function in cancer is still controversial, with the majority of authors hypothesizing an oncogenic role based on its upregulation in several human malignancies (i.e., colorectal, breast, prostate, nasopharyngeal, and lung carcinomas), whereas others suggesting an oncosuppressive function due to its downregulation in select tumors (i.e., ovarian, renal, and cervical carcinomas) along with tumor progression [5,9]. Noteworthy, TRAP1 expression inversely correlates with the activity of succinate dehydrogenase and cytochrome c oxidase, with consequent downregulation of OXPHOS in human malignancies with high TRAP1 expression [15,16] and upregulation of oxidative metabolism in tumors with low TRAP1 background [14]. Consistently, high TRAP1 expression may favor glycolytic metabolism through modulation of hexokinase activity [17]. Altogether, these pieces of evidence suggest that TRAP1 role in bioenergetics is cell- and context-dependent and that cancer cells up/downregulate TRAP1 expression to adapt their bioenergetics to energy requirements and environmental conditions [5]. To further characterize mechanisms involved in the regulation of glycolysis by TRAP1, this study addresses the mechanisms of TRAP1 regulation of glycolytic pathway, showing for the first time a new interaction between TRAP1 and the most relevant glycolytic enzyme PFK1 and the relationship between TRAP1 glycolytic regulation and its control of mitochondrial respiration in colorectal carcinoma cells (CRCs). Remarkably, the impact of this regulation in modulating cancer cell response to EGFR inhibitors is shown. This issue is extremely relevant in a clinical perspective, since TRAP1 is upregulated in colorectal carcinogenesis at the transition between low- and high-grade adenomas and in about 60% of human CRCs with parallel overexpression of its protein network [18] and this favors a drug-resistant phenotype [19,20]. Intriguingly, the co-upregulation of TRAP1 and 6-proteins of TRAP1 protein network identifies a subgroup of metastatic CRCs (mCRCs) with poor outcome [18].

2. Materials and methods

2.1. Tumor specimens, clinical data, chemicals, patient-derived spheroids, and cell cultures

Specimens from 26 human CRCs and corresponding normal, non-infiltrated peritumoral mucosa were obtained from the IRCCS-CROB Tissue Biobank (Cohort 1). Tumors were staged according to TNM classification system [21] and were selected for having been evaluated with 18F-fluoro-2-deoxy-glucose (18F-FDG) positron emission tomography (PET) imaging before surgical removal of primary tumors. The maximum standardized uptake values (SUVmax) body weight corrected were determined in primary tumors using vendor-provided software (Volumetrix for PETCT; GE Healthcare, Waukesha, WI, USA) and further used to establish statistical correlations with molecular data. Patient’s characteristics are reported in Table S1 (Cohort 1).

An additional cohort of 15 RAS-wild-type mCRCs treated with first-line standard doublet chemotherapy...
(FOLFIRI or FOLFOX regimens) combined with cetuximab was selected to study the relationship between glycolytic metabolism and response to cetuximab (Table S1, Cohort 2). Patients were deemed eligible if they met the following requirements: (a) primary surgery without neo-adjuvant chemo-radiotherapy; (b) 18F-FDG PET scan before first-line therapy, and (c) follow-up CT scan within 3 months from beginning of first-line therapy to assess tumor response. Using the above criteria, 25 target lesions were evaluated. Imaging studies were interpreted by two experienced nuclear medicine physicians. The mass sizes were visually estimated and measured for minimum and maximum diameters by using vendor-provided based software both on aggregated initial PET/CT and on subsequent CT scan. Target lesions were defined as identifiable masses/structural lesions or lymph nodes larger than 1 cm in minimum diameter with soft-tissue/abdominal window settings (i.e., one lymph node > 1 cm or three lymph nodes in cluster) matching with a significant 18F-FDG uptake on PET scan. The maximum standardized uptake values (SUVmax) body weight corrected in target lesions was used for further analyses. PET studies were evaluated both visually and semiquantitatively (SUVmax) using a conventional SUVmax cutoff value of 2.5 (significant uptake) which has been considered to provide excellent specificity and sensitivity for detecting lesions [22]. Tumor response was assessed based on RECIST criteria [23]. Patients were considered responders in case of complete (i.e., disappearance of all target lesions) or partial response (i.e., at least a 30% decrease in the sum of the longest diameter of target lesions). Progressive disease was defined as at least 20% increase in the sum of the longest diameter of target lesions or the appearance of one or more new lesions; stable disease was defined as either not sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Patient’s characteristics are reported in Table S1 (Cohort 2). All patients gave their informed written consent to use biological specimens and clinical data for investigational procedures. The study methodologies were approved by the local ethics committee (PROT. N. 20120010288 Titolo: ‘Ruolo del pathway citoprotettivo di TRAP1 e HSP90 nei tumori umani del colon-retto e della mammella’-P.I. Prof. M. Landriscina).

Unless otherwise specified, reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human CRC HCT116, HT29, CaCo2, and NCIH508 cells were purchased from American Type Culture Collection (ATCC), (Manassas, VA, USA). Cell lines were routinely monitored in our laboratory by microscopic morphology, while cell line authentication was verified before starting this study by STR profiling, according to ATCC product description. TRAP1-stable interfered HCT116 cells were cultured as previously described [24]. Spheroids derived from human CRCs were kindly provided by Prof. Ruggero De Maria (General Pathology Institute, Catholic University, Rome, Italy). Spheroids were cultured in ultralow attachment tissue culture flasks (Corning Costar, Cambridge, MA, USA) in humidified atmosphere at 37 °C and 5% CO2 in a medium containing Advanced DMEM F12 supplemented with 10 mM HEPES, 100 ng·mL−1 human recombinant bFGF, 10 mM nicotinamide, 2 mM L-glutamine, 100 U·mL−1 P/S, N2 supplement 1×, B27 supplement 1×, 50 ng·mL−1 human recombinant EGF (Thermo Fisher Scientific, Waltham, MA, USA). Spheroids were passaged weekly by mechanical dissociation or by incubation for 3–5 min at 37 °C with TrypLE Express (Thermo Fisher).

2.2. Transfection procedures

TRAP1 and BRAF transient silencing were performed with siRNAs purchased from Qiagen (Milano, Italy; cat. No° SI00115150 for TRAP1, cat. No° SI00299488 for BRAF and cat. No° SI0040663 for PFK1). For control experiments, cells were transfected with a similar amount of control siRNA (Qiagen; cat. no. SI03650318). Transient transfections of siRNAs were performed using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer’s protocol. Full-length TRAP1 cDNA, TRAP1 deletion mutant Δ1-59 TRAP1-Myc [20,24], and BRAF V600E (kindly provided by M. Santoro, University of Naples) [25] constructs were cloned in pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) and transiently transfected using the PolyFect Transfection Reagent (Qiagen) according to the manufacturer’s protocol. TRAP1 stable interference was achieved by transfecting HCT116 cells with TRAP1 (TGCTGTGTGAGTGAGCGACCGGTTC CCTGTACTCAGAAATAGTGAAGCCACAGATG ATTTCTGAGTACAGGGACCGGGCTGCCTACTG CCTCGGA) or scrambled (sequence containing no homology to known mammalian genes) shRNA (Open Biosystem, Huntsville, AL, USA) [20].

2.3. Immunoblot analysis

Cell pellets and tumor samples were lysed in ice-cold RIPA buffer as described in Landriscina et al. [20]. Subcellular fractions were purified by Qproteome Mitochondria Isolation Kit (Qiagen), according to
manufacturer’s protocol. Immunoblot analysis was performed as previously reported [20]. Protein immunoprecipitation was carried out starting from 1 mg of total protein extracts by Pierce Classic IP Kit (Thermo Scientific) according to manufacturer’s protocol. Protein levels were quantified by densitometric analysis using the QUANTITY ONE 4.5 software (Bio-Rad Laboratories GmbH, Hercules, CA, USA) and normalized for the respective housekeeping gene. TRAP1 and GLUT1 expression in tumors was considered upregulated if > 3 times compared to expression levels in normal non-infiltrated peritumoral mucosa [19]. This cutoff was determined by applying Youden’s index [26]. The following antibodies from Santa Cruz Biotechnology (Dallas, TX, USA) were used as follows: mouse monoclonal anti-HSP75 (TRAP1, sc-73604), mouse monoclonal anti-BRAF (sc-5284), mouse monoclonal anti-PFK1 (sc-514824), rabbit polyclonal anti-MCT4 (sc-50329), mouse monoclonal anti-ACTIN (sc-47728), mouse monoclonal anti-Tubulin (sc-8035), rabbit polyclonal anti-Calnexin (M-108, sc-5627), and mouse monoclonal anti-GAPDH (sc-47724). The following antibodies were also used as follows: rabbit polyclonal anti-PFK1 (ab154804; Abcam, UK), rabbit polyclonal anti-GLUT1 (ab32551; Abcam, Cambridge, UK), and rabbit polyclonal anti-Hexokinase II (cat. n. 2867S; Cell Signaling, Danvers, MA, USA).

2.4. Proximity ligation assay

Cells were seeded on coverslips and, after 48 h, fixed with 4% (w/v) paraformaldehyde in PBS for 20 min. Cells were blocked and permeabilized with 0.4% (w/v) BSA, 0.1% (v/v) Triton X-100, 5% (v/v) FBS in PBS for 15 min at RT before staining over night with indicated primary antibodies. The Duolink In Situ Red Starter Kit Mouse/Rabbit from Sigma-Aldrich (DUO92101) was used, according to the manufacturer’s instructions. Image acquisition was performed by confocal laser-scanning microscopy using Zeiss 510 LSM from Carl Zeiss Microimaging (Oberkochen, Germany).

2.5. Metabolic assays

Glucose uptake was evaluated by both colorimetric and radioactive assays, measuring, respectively, 2-DG and 18F-FDG uptake. Colorimetric assay was used according to the manufacturer’s protocol (ab136955; Abcam). Radioactive assay was previously described by Maddalena et al. [27].

Lactate production, phosphofructokinase (PFK) 1 and hexokinase (HK) II activities, and citrate concentration were measured using, respectively, the Lactate Assay Kit (Abcam ab65331), the Sigma-Aldrich MAK093 and the Abcam ab136957 colorimetric assays and the Citrate Assay Kit (Sigma-Aldrich MAK057), according to the manufacturer’s instructions. Oxygen consumption rates (OCR) in intact cells were measured by Hansatech Oxygraph in a thermostatically controlled chamber (T = 37 °C) equipped with a stirring device and a gas-tight plug with a narrow port enabling addition by microsyringe. Cultured cells were detached, centrifuged at 290 g for 5 min, and resuspended in standard medium. After stabilization of the oxygraph baseline signal, the cell suspension was added into the reaction chamber at the desired concentration (typically 15–20 × 10⁶ cells·mL⁻¹). After achievement of the stationary resting oxygen consumption rate (OCRᵣ), 1.0 µg·mL⁻¹ of oligomycin was added in order to determine the ATP-linked respiration (OCRₒ), followed by the addition of 10 µM of the uncoupler FCCP to obtain the maximal respiratory activity (OCRᵤ). The measured OCRs were corrected for the 2 µM rotenone-insensitive respiration, to be attributable to the mitochondrial respiration, and normalized to the cell number. In specific experiments (Fig. 4), glycolytic metabolism and OXPHOS were measured with Seahorse XF24 Extracellular Flux Analyzer (Agilent, Santa Clara, CA, USA) according to the manufacturer’s instructions. Briefly, HCT116 cells were grown in Mc’Coys supplemented with 10% FBS. Twelve hours before the experiment, 1.2 × 10⁴ cells were seeded in a 96-well microplate, and sodium pyruvate, metabolic drugs, or PBS were injected during measurements.

2.6. Cell cycle detection

Cells were plated into 6-well plates and treated as reported in figure legends, incubated in a culture medium supplemented with 20 µmol·L⁻¹ 5-bromo-2’-deoxyuridine (BrdUrd) for 20 min, harvested, washed, and fixed in cold 70% ethanol overnight at 4 °C. After fixation, samples were prepared as reported in Sisinni et al. [28]. Finally, samples were analyzed using the FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA).

2.7. Statistics

The Mann–Whitney test was used to establish the statistical significance between different levels of gene expression in Real-time PCR analysis, metabolic results, or cells in S-phase in silenced/transfected/treated cell lines and related controls. The ANOVA and
Bonferroni test was used to compare more than two groups. Data are reported as mean value of least three independent experiments (±SD). The Spearman test was used to establish statistical significance of TRAP1, GLUT1 and SUV correlation in human CRCs.

3. Results

3.1. TRAP1 levels correlate with GLUT1 expression and 18F-FDG uptake in human colorectal carcinomas

The expression of TRAP1 and GLUT1 was analyzed in 26 human CRCs enrolled in this study for having been evaluated by 18F-FDG PET scan before surgical intervention (Table S1, Cohort 1). Interestingly, the expression of TRAP1 was confirmed to be upregulated in 73% of primary CRCs, whereas GLUT1 was overexpressed in 65% of cases (Fig. 1A,B and Table S2). The Spearman correlation test showed a week, but statistically significant correlation between TRAP1 protein levels and glucose uptake (measured as standardized uptake value upon PET scan; Fig. 1C) and a more robust correlation between TRAP1 and GLUT1 expression (Fig. 1D). As expected, a correlation was also observed between SUV upon 18F-FDG PET imaging and GLUT1 protein levels (Fig. S1). These results suggest that TRAP1 is involved in the glycolytic phenotype of human CRCs.

3.2. TRAP1 regulates the balance between glycolysis and oxidative metabolism in human colorectal carcinoma cell lines

TRAP1 role in metabolism was further explored in CRC cell lines transiently silenced for TRAP1 expression to evaluate lactate production and oxygen consumption rate (OCR). Results from independent siTRAP1 preparations with different efficiency of protein expression, reported as percentage of the corresponding mock controls, suggest a linear correlation between TRAP1 protein expression and lactate production in HCT116 cells (Fig. 2A) and an inverse correlation between TRAP1 protein levels and mitochondrial respiratory activity with OCR progressively increased upon TRAP1 downregulation (Fig. 2A). Row data of these experiments are reported in Fig. S2A. The dependency of lactate production from TRAP1 expression was confirmed upon transient or stable TRAP1 knock down in, respectively, HT29 (Fig. 2B) and HCT116 (Fig. 2C and Fig. S2B). Consistently, glucose uptake was significantly decreased by 40–60% after transient/stable TRAP1 silencing in HT29 (Fig. 2B) and HCT116 (Fig. 2C and Fig. S2B). Finally, a significant reduction in the expression of the plasma membrane glucose transporter, GLUT1 and the lactate transporter, MCT4 was observed in HCT116 and HT29 cells upon TRAP1 silencing (Fig. 2B,C and Fig. S2B, inserts). Since HCT116 and HT29 cells are routinely cultured in the presence of high glucose (16.6 mm), to rule out the hypothesis that the glycolytic profile of CRC cell lines with high TRAP1 expression may depend on glucose concentration, metabolic parameters were measured in HCT116 cells cultured in more physiologic glucose concentration (5.5 mm) upon TRAP1 silencing. As reported in Fig. S2C,D, TRAP1 effect on glycolytic metabolism and OXPHOS is preserved, although attenuated, even in the presence of low glucose. Indeed, glucose uptake and lactate production are significantly reduced upon TRAP1 silencing (Fig. S2C) and this is paralleled by a significant increase in OCR (Fig. S2D). Altogether, these data suggest that high TRAP1 expression favors glycolytic metabolism in human CRC cells.

3.3. TRAP1 glycolytic phenotype is independent from its quality control on BRAF

Since TRAP1 is responsible for quality control of BRAF protein synthesis [25] and BRAF signaling enhances Warburg metabolism [29,30], the hypothesis that TRAP1 regulation of glucose metabolism may occur through the modulation of BRAF signaling was further evaluated. To this purpose, glucose uptake and lactate production were evaluated in BRAF V600E HT29 cells upon BRAF silencing and parallel TRAP1 upregulation (Fig. S3A). Interestingly, while BRAF downregulation induced a statistically significant inhibition of both glucose uptake and lactate production, TRAP1 overexpression completely rescued the effect of BRAF silencing on glucose metabolism (Fig. S3A). Interestingly, while BRAF downregulation induced a statistically significant inhibition of both glucose uptake and lactate production, TRAP1 overexpression completely rescued the effect of BRAF silencing on glucose metabolism (Fig. S3A). In parallel experiments, BRAF V600E mutant was upregulated in TRAP1-silenced HCT116 cells and cell lines evaluated for glucose uptake and lactate production (Fig. S3B). Indeed, BRAF upregulation resulted in a marked increase of 2-DG uptake and a more modest increase in lactate production. However, the downregulation of both glucose uptake and lactate production in a low TRAP1 background was conserved independently from BRAF V600E mutant upregulation (Fig. S3B). These results suggest that TRAP1 regulation of glucose metabolism is independent from its quality control on BRAF synthesis.
3.4. TRAP1 enhances glycolysis through regulation of PFK1 activity/expression

To dissect the molecular mechanism underlying TRAP1 regulation of glycolytic metabolism, we took advantage from our list of putative TRAP1 interactors, obtained by proteomic analysis of TRAP1 immunoprecipitates [20], which, among others, identified phosphofructokinase-1 (PFK1), a key glycolytic enzyme [31]. Noteworthy, the direct protein–protein interaction between TRAP1 and PFK1 was confirmed in HCT116 cells by in situ proximity ligation assay (Fig. 3A). Since TRAP1 is a molecular chaperone responsible for cotranslational quality control on nascent polypeptides [32], PFK1 expression and activity were evaluated upon TRAP1 silencing in HCT116 cells cultured in standard medium or in the presence of low glucose. Indeed, PFK1 protein level (Fig. 3B and Fig. S4A) and activity (Fig. 3C) were conserved in a high TRAP1 background, but significantly reduced upon TRAP1 transient silencing (Fig. 3B,C). Similar data were observed in HCT116 cells cultured in low glucose (Fig. S4B). Hexokinase II (HKII) protein level and activity were unchanged in the same experimental conditions (Fig. 3B,C). Of note, no significant modification of PFK1 mRNA expression was observed under TRAP1 silencing conditions (Fig. S4C).

Based on the rationale that colon cancer stem cells (CSCs) are characterized by a predominant glycolytic metabolism [33,34] and that TRAP1 is upregulated in colon CSCs and involved in their maintenance [11], patient-derived CRC spheres, known to be enriched in CSCs [35], were evaluated to further establish the relationship between TRAP1, PFK1 activity/expression, and lactate production. Interestingly, TRAP1 silencing resulted in parallel downregulation of PFK1 protein levels (Fig. 3D) and activity and lactate production (Fig. 3E) in patient-derived SA54 CRC spheres, this confirming analogous data shown in Fig. 3B,C.

In order to evaluate whether TRAP1 regulation of Warburg metabolism depends on its effect on PFK1 activity, PFK1 was knocked down in TRAP1-overexpressing HCT116 cells. Of note, while TRAP1 upregulation resulted in enhanced PFK1 expression/activity and lactate production, PFK1 protein/activity downregulation in a high-TRAP1 background significantly
inhibited lactate production (Fig. 3F,G). Consistently, PFK1 expression/activity was reduced in stable TRAP1 silenced HCT116 cells and TRAP1 re-expression in a low TRAP1 background resulted in enhanced PFK1 expression/activity and lactate production (Fig. S4D). Finally, PFK1 was re-expressed in shTRAP1 HCT116 cells, thus resulting in a partial, but statistically significant re-establishment of PFK1 activity and lactate production (Fig.3H,I). Altogether, these data suggest that TRAP1 modulates glycolytic metabolism through the regulation of PFK1 activity/expression.

3.5. TRAP1 regulation of glycolytic metabolism and PFK1 activity depends on mitochondrial respiratory capacity

In order to evaluate the role of TRAP1 in regulating the balance between glycolytic and oxidative metabolism in CRC cell lines, we generated a model of cell supplementation with pyruvate to boost OXPHOS. Cell metabolism was analyzed by Seahorse technology to evaluate in parallel mitochondrial OCR (Fig. 4A) and extracellular acidification rate (ECAR; Fig. 4B) upon TRAP1 silencing; PFK1 activity was evaluated in the same experimental conditions (Fig. 4C). As previously observed, high TRAP1 expression correlated with lower OCR (Mann–Whitney test: P < 0.05; Bonferroni post hoc test: P < 0.05) and higher ECAR (Mann–Whitney test: P < 0.05; Bonferroni post hoc test: P < 0.01) and PFK1 activity (Mann–Whitney test: P < 0.05; Bonferroni post hoc test: P < 0.001) in standard conditions (lack of pyruvate supplementation). As expected, pyruvate supplementation enhanced OCR independently from TRAP1 expression with maximal induction in conditions of TRAP1 silencing (Mann–Whitney test: P < 0.05) and this was paralleled by downregulation of ECAR (Mann–Whitney test: P < 0.05) and PFK1 activity (Mann–Whitney test: P < 0.05) to levels observed in conditions of low TRAP1 background. Since these data suggest that TRAP1 regulation of PFK1 activity occurs to balance...
the suppression of OXPHOS, TRAP1-silenced cells were treated with UK5099, a pharmacological inhibitor of pyruvate transport in mitochondria. Interestingly, inhibition of pyruvate uptake into mitochondria resulted in a significant inhibition of OCR (Mann–Whitney test: \( P < 0.05 \); Bonferroni post hoc test: \( P < 0.01 \)) and re-establishment of TRAP1 control of ECAR (Mann–Whitney test: \( P < 0.05 \); Bonferroni post hoc test: \( P < 0.05 \)) and PFK1 activity (Mann–Whitney test: \( P < 0.05 \); Bonferroni post hoc test: \( P < 0.001 \)). These data suggest that TRAP1 regulation of lactate production and PFK1 activity is maximized in conditions of low OXPHOS.

Citrate is an intermediate product of tricarboxylic acid (TCA) and an allosteric inhibitor of PFK1, known to slow glycolysis, enhance OXPHOS, and link mitochondrial TCA cycle with rate of glycolysis [36,37]. Thus, citrate levels were evaluated in HCT116 cells supplemented with pyruvate and/or silenced for TRAP1. Interestingly, citrate levels were
confirmed to be increased in HCT116 cells incubated in the presence of pyruvate and silenced for TRAP1, both conditions of enhanced mitochondrial respiration (Fig. 5A). Thus, to test the role of citrate in TRAP1 regulation of the balance between glycolysis and OXPHOS, TRAP1-silenced HCT116 cells were supplemented with citrate and evaluated for lactate production and PFK1 activity in comparison with cell cultures supplemented with pyruvate. Noteworthy, both lactate production (Fig. 5B) and PFK1 activity (Fig. 5C) were maximal in TRAP1-expressing cells cultured in the absence of pyruvate; by contrast, citrate supplementation, as observed for pyruvate supplementation, resulted in the loss of TRAP1 capacity to enhance lactate production and PFK1 activity. Altogether, these data suggest that TRAP1 regulates Warburg metabolism to balance modification of OXPHOS and that this process occurs through intermediates of the TCA cycle and the modulation of PFK1 activity/expression.

3.6. TRAP1 regulation of PFK1 glycolytic activity depends on their interaction on the endoplasmic reticulum

TRAP1 interacts with its client proteins (i.e., sorcin, BRAF, CDK1, F1ATPase) and is responsible for their quality control through the cooperation with the proteasome regulatory particle, TBP7 [20,24,25,28]. Thus, we hypothesized that PFK1 is among TRAP1 client proteins whose activity is regulated upon their reciprocal interaction. Thus, the interaction between TRAP1 and PFK1 was investigated by co-immunoprecipitation (co-IP) experiments in total lysate and endoplasmic reticulum (ER) fraction of HCT116 cells. Indeed, PFK1 immunoblot analysis of TRAP1 co-immunoprecipitates detected an 84 kDa band in both total lysate and the ER fraction (Fig. 6A, left panel). Consistently, TRAP1 immunoblot analysis of PFK1 co-immunoprecipitates detected a 75 kDa band only in the ER fraction (Fig. 6A, right panel). Since PFK1 activity is
downregulated upon pyruvate supplementation, PFK1 co-immunoprecipitation was evaluated in the presence of pyruvate to address the hypothesis that TRAP1/PFK1 interaction is relevant for PFK1 activity regulation. PFK1 co-immunoprecipitation was evaluated also upon incubation with antimycin A, an inhibitor of cellular respiration, as a control. Noteworthy, pyruvate supplementation, but not OXPHOS inhibition, resulted in loss of PFK1/TRAP1 interaction, being PFK1 detected in TRAP1 co-immunoprecipitates only in cells cultured in standard conditions (lack of pyruvate) or exposed to antimycin A (Fig. 6B). In addition, since TRAP1 silencing results in downregulation of PFK1 protein level/activity, we hypothesized that the downregulation of PFK1 may be dependent on increased ubiquitination/degradation of the inactive protein. Thus, ubiquitinated proteins were immunoprecipitated from TRAP1-silenced HCT116 cells and further evaluated by anti-PFK1 antibodies to assess the level of ubiquitinated PFK1. Noteworthy, PFK1 immunoblot analysis of anti-ubiquitin immunoprecipitates showed increased levels of PFK1 polyubiquitination in TRAP1-interfered cells despite the overall reduction in PFK1 levels in total lysates (Fig. 6C) and this is consistent with increase in overall protein ubiquitination in TRAP1-silenced cells (Fig. 6C, insert). Finally, since TRAP1 is mostly localized in mitochondria (Fig. S5A), in order to further characterize the

Fig. 5. TRAP1 regulation of PFK1 and glycolytic metabolism depends on citrate production. (A) Citrate concentration in TRAP1-silenced HCT116 cells cultured in standard medium (no pyruvate) or supplemented with 10 mM pyruvate for 6 h. (B, C) Relative lactate production (B) and PFK1 activity (C) in TRAP1-silenced HCT116 cells cultured in standard medium (no pyruvate), or supplemented with 10 mM pyruvate or 1 mM citrate for 6 h. Insert: PFK1 and TRAP1 immunoblot analysis in TRAP1-silenced HCT116 cells cultured in standard medium (no pyruvate) or supplemented with 10 mM pyruvate or with 1 mM citrate for 6 h. Graphs represent mean ± SD of three experiments. The Mann–Whitney test was used to establish the statistical significance between two groups (P < 0.05). (A) ANOVA test: P = 0.0005; Bonferroni post hoc test: no pyr: P < 0.05, pyr: P > 0.001; pyr+UK5099: P < 0.001. (B) ANOVA test: P = 0.003; Bonferroni post hoc test: no pyr: P < 0.01; pyr: P > 0.05; pyr+UK5099: P < 0.003. (C) ANOVA test: P = 0.0027; Bonferroni post hoc test: no pyr: P < 0.001; pyr: P > 0.05; pyr+UK5099: P < 0.001.
role ER-associated TRAP1 in regulating Warburg metabolism, shTRAP1 HCT116 cells were transfected with a TRAP1 deletion mutant lacking the mitochondrial targeting sequence and unable to accumulate in mitochondria (D1-59 TRAP1-Myc; Fig. S5B) [24] and evaluated for PFK1 expression/activity and lactate production. Noteworthy, the upregulation of the ER-associated TRAP1 deletion mutant in a low TRAP1 background rescued PFK1 expression/activity and lactate production (Fig. S5C). These data suggest that TRAP1 and PFK1 interact on the ER and that this interaction is relevant to maximize PFK1 glycolytic activity, being the protein ubiquitinated and degraded in a low TRAP1 background.

### 3.7. Inhibition of TRAP1-dependent glycolytic phenotype potentiates cell response to EGFR inhibition

Several observations suggest that high glycolytic metabolism favors resistance to EGFR inhibitors in lung carcinoma [38]. Therefore, the relationship between TRAP1 expression, glycolytic metabolism, and response to cetuximab was investigated in RAS-wild-type CRC cells and CRC spheres. In preliminary experiments, PFK1 expression/activity and glycolytic metabolism were evaluated in RAS-wild-type NCIH508 (Fig. 7A) and CaCo2 (Fig. S6) cells upon exposure to cetuximab. Interestingly, EGFR inhibition resulted in downregulation of TRAP1, PFK1 expression/activity, and lactate production in NCIH508 cells (Fig. 7A) and TRAP1, PFK1, and MCT4 expression in CaCo2 cells (Fig. S6). Thus, TRAP1 was upregulated in NCIH508 cells and cells were evaluated for Warburg metabolism (Fig. 7B) and cell cycle progression (Fig. 7C) in response to cetuximab. Noteworthy, while TRAP1 upregulation resulted in enhancement of PFK1 protein expression/activity and lactate production (Fig. 7B), cetuximab failed to significantly downregulate PFK1 expression/activity and lactate production (Fig. 7B) and cell cycle progression (Fig. 7C) in NCIH508 cells with high TRAP1 background. In parallel experiments, cetuximab activity was evaluated by a spheroid-formation assay (Fig. 7D and Fig. S7) and for its capacity to inhibit lactate production and PFK1 activity in RAS-wild-type CRC spheres (Fig. 7E). Noteworthy, cetuximab showed poor inhibitory activity as single agent (Fig. 7D and Fig. S7) and the inhibition of Warburg metabolism by 2DG, an inhibitor of glycolysis, 3PO, an inhibitor of PFK1, or TRAP1 silencing resulted in attenuation of spheroid formation (Fig. 7D and Fig. S7) and a parallel inhibition of lactate production and PFK1 activity (Fig. 7E). Noteworthy, the combination of cetuximab with 2DG, 3PO, or TRAP1 interference significantly inhibited colony formation (Fig. 7D and Fig. S7) as well as lactate production and PFK1 activity (Fig. 7E).

Consistently, cell cycle progression (Fig. S8A), lactate production, and PFK1 activity (Fig. S8B) were evaluated in RAS-wild-type Caco2 cells in the same experimental conditions. Indeed, CaCo2 cells showed a minimal/moderate inhibition of cell cycle progression (Fig. S8A), lactate production, and PFK1 activity (Fig. S8B) in response to cetuximab, 2DG, 3PO, or upon TRAP1 silencing. Noteworthy, the combination of cetuximab with 2DG, 3PO, or TRAP1 interference resulted in a more profound inhibition of cell cycle progression (Fig. S8A), lactate production, and PFK1 activity (Fig. S8B). These data suggest that the pharmacological inhibition of EGFR is partially impaired by high Warburg metabolism in RAS-wild-type CRC cells and spheres. Consequently, we addressed the hypothesis that high glycolytic metabolism may result in poor cetuximab activity in human metastatic CRCs (mCRCs). To this aim, we analyzed a cohort of 15 human RAS-wild-type mCRCs treated with first-line chemotherapy combined with cetuximab and evaluated by 18F-FDG PET scan before therapy and CT scan after therapy (Table S1, cohort 2). Response to therapy was evaluated by RECIST criteria based on CT imaging and correlated with 18F-FDG uptake at baseline. Noteworthy, 18F-FDG uptake was significantly higher in progressing compared to responding (SUV, 9.8 ± 0.8 vs 4.5 ± 1.1; P < 0.0001) or stable tumors (SUV, 9.8 ± 0.8 vs 5.3 ± 1.5; P = 0.0007) and a direct correlation was observed between 18F-FDG SUV and lack of response to cetuximab (Spearman correlation test, R = 0.555908, P = 0.004; Fig. 7F). Altogether, these data provide the proof of concept that metabolic remodeling is a mechanism to escape from EGFR inhibition in RAS-wild-type mCRCs and that TRAP1 targeting may represent a strategy to enhance cell response to cetuximab.

### 4. Discussion

Molecular chaperones are involved in cancer cell adaptation to stress conditions, that is, unfavorable environments, hypoxia, ER stress, metabolic stress, drug therapy, and their upregulation is widely considered a mechanism of cancer progression [9,19,39–44]. Furthermore, metabolic rewiring is used by cancer cells to adapt to environmental stresses and molecular chaperones are hub proteins connecting different metabolic pathways and favoring cancer cell reprogramming [5,45]. We previously demonstrated that TRAP1
protein network is upregulated in human CRCs [18,19] and its high expression correlates with poor clinical outcome [18], drug resistance [19], and suppression of mitochondrial respiration [15]. Herein, we tested the hypothesis that TRAP1 favors metabolic adaptation in human CRC. Our data suggest that (a) high TRAP1 expression correlates with enhancement of Warburg metabolism in human CRC samples, patient-derived spheroids, and cell lines; (b) TRAP1 control of glycolysis depends on its interaction with PFK1 on endoplasmic reticulum with regulation of PFK1 activity/stability; and (c) TRAP1 modulates glycolysis and PFK1 activity to balance modifications of mitochondrial respiration. Clinically relevant is the observation that cetuximab activity is partially impaired in high TRAP1 background and increased Warburg metabolism and that high PET18F-FDG uptake at baseline results in lower cetuximab activity in mCRC first-line therapy.

These observations shed light on TRAP1 regulation of cancer metabolism and its involvement in CRC biology. Intriguingly, TRAP1 is a key regulator of the balance between oxidative and glycolytic metabolism and high TRAP1 expression favors Warburg metabolism. Indeed, TRAP1 suppresses mitochondrial respiration upon interaction/inhibition of complexes II and IV of the respiratory chain [15,16] and concomitantly enhances GLUT1 expression, glucose uptake, PFK1 activity/stability, and lactate production. Thus, human malignancies with high TRAP1 expression, and CRCs among others, are characterized by a predominant glycolytic metabolism [15,16, and this study] whereas human tumors with TRAP1 downregulation show mostly an oxidative metabolism [14]. Mechanistically,
TRAP1 regulation of glycolysis relies primarily on its capacity to interact with PFK1 likely on the ER and enable PFK1 glycolytic activity preventing its ubiquitination/degradation (see the Graphical Abstract). This mechanism is consistent with previous observations by our group showing that TRAP1 is associated with the ER membranes, facing the cytosol [24] and plays a cotranslational quality control on a network of client proteins (i.e., sorcin, F1ATPase, BRAF, CDK1) which yields enhancement of their expression and lowers

![Graphical Abstract](image_url)

**Fig. 7.** High TRAP1 expression and glycolytic metabolism correlate with poor response to cetuximab in vitro and in vivo. A. Relative lactate production and PFK1 activity in RAS-wild-type NCIH508 cells incubated with 17 nm cetuximab for 15 h. Insert: PFK1 and TRAP1 immunoblot analysis in NCIH508 cells incubated with 17 nm cetuximab for 15 h. (B, CI Relative lactate production and PFK1 activity (B) and cell cycle distribution (CI) in NCIH508 cells transfected with TRAP1 cDNA and incubated with 17 nm cetuximab for 15 h. (B) Insert: PFK1 and TRAP1 immunoblot analysis in NCIH508 cells transfected with TRAP1 cDNA and incubated with 17 nm cetuximab for 15 h. (D, E) Number of spheroid (D), relative lactate production and PFK1 activity (E) in RAS-wild-type patient-derived CRC spheroids (SA54 cells) incubated with 680 nm cetuximab, 10 µM 2DG, 10 µM 3PO for 48 h or silenced for TRAP1 or exposed to the combination of cetuximab and 2DG, 3PO, or TRAP1 silencing. Spheroids were counted if they were ≥ 40 µm in size. (D) Insert: TRAP1 and PFK1 immunoblot analyses in patient-derived spheroids silenced for TRAP1. (F) Plot representing the relationship between 18FDG PET uptake at baseline and percent of size variation of target lesions according to RECIST criteria in mCRCs treated with first-line chemotherapy combined with cetuximab. Graphs represent mean ± SD of three experiments. The Mann-Whitney test was used to establish the statistical significance between two groups \(P < 0.05\). B. ANOVA test: \(P = 0.002\); Bonferroni post hoc test: CTRL pmock vs CTX pmock, lactate production: \(P < 0.001\), PFK1 activity: \(P < 0.001\); CTRL pTRAP1 vs CTX pTRAP1, lactate production: \(P > 0.05\), PFK1 activity: \(P > 0.05\); CTRL pmock vs CTRL pTRAP1, lactate production: \(P < 0.001\), PFK1 activity: \(P < 0.001\). D. ANOVA test: \(P = 0.01\); Bonferroni post hoc test: CTRL vs CTX \(P > 0.05\); CTRL 2-DG vs CTX 2-DG \(P < 0.001\); CTRL 3PO vs CTX 3PO \(P < 0.001\); siTRAP1 vs siTRAP1 CTX \(P < 0.001\). E. ANOVA test: \(P < 0.007\); Bonferroni post hoc test: CTRL vs CTX lactate production: \(P = 0.05\), PFK1 activity: \(P < 0.001\); CTRL 2-DG vs CTX 2-DG lactate production: \(P < 0.001\), PFK1 activity \(P < 0.001\); CTRL 3PO vs CTX 3PO lactate production: \(P < 0.001\), PFK1 activity: \(P < 0.001\); siTRAP1 vs siTRAP1 CTX lactate production: \(P < 0.01\), PFK1 activity: \(P < 0.001\).
their proteasomal degradation [9]. This TRAP1 function is relevant for its regulation of specific cell functions and for its role in tumor progression. In such a view, TRAP1 enhancement of Warburg metabolism is likely crucial in supplying cancer cells with metabolic substrates and energetic molecules to support biosynthetic processes and cell proliferation.

It is intriguing that TRAP1 regulation of PFK1 activity is finalized to maximize Warburg metabolism in response to the downregulation of mitochondrial respiration. Conditions of poor mitochondrial respiration (i.e., lack of pyruvate or inhibition of pyruvate uptake by mitochondria, which prevents its entry in TCA cycle) [46] maximize TRAP1 capacity to enhance PFK1 activity and lactate production. Consistently, supplementation with pyruvate, which drives acetyl-CoA production, enters in the TCA cycle and enhances mitochondrial respiration [47], results in loss of TRAP1 interaction with PFK1 and parallel lowering of PFK1 activity and glycolytic metabolism. Mechanistically, this interplay is dependent on both TRAP1 expression, which prevents PFK1 ubiquitination/degradation, and levels of citrate, a metabolic product of TCA cycle and an allosteric inhibitor of PFK1 [37,48]. Indeed, citrate levels are higher in cell supplemented with pyruvate and/or silenced for TRAP1, both conditions characterized by an enhancement of OXPHOS. Consistently, cell supplementation with citrate, mimicking its enhanced production by mitochondrial respiratory chain, results in downregulation of PFK1 activity and loss of TRAP1 control of glycolysis. Thus, TRAP1 favors Warburg metabolism by maximizing PFK1 activity/stability to balance the downregulation of mitochondrial respiration. Remarkably, this mechanism is likely used to regulate tumor metabolic state depending on energetic requirements and extracellular stresses (see the Graphical Abstract).

Clinically relevant is the observation that high glycolytic metabolism results in poorer response to cetuximab in RAS-wild-type mCRCs, spheroids, and cell lines. Indeed, PFK1 expression and lactate production are under the control of EGFR signaling in CRC cells (this study) as previously observed in head and neck carcinoma cells [49]. Furthermore, TRAP1 upregulation and the parallel enhancement of glycolytic metabolism correlate with lower response to EGFR inhibition in cetuximab-sensitive CRC cells. The inhibition of glycolytic metabolism or TRAP1 knockdown in combination with cetuximab results in downregulation of lactate production and, interestingly, improved cetuximab cytostatic activity in patient-derived spheres and immortalized cell lines. Finally, high 18F-FDG PET uptake correlates with poor/lack of response to cetuximab first-line combination chemotherapy in RAS-wild-type mCRCs. Thus, CRC cells may use metabolic rewiring to escape EGFR inhibition and this may account for poor response to EGFR inhibitors in a subgroup of human RAS-wild-type mCRCs [50]. Indeed, much evidence supports the role of metabolic plasticity of cancer cells in drug resistance [51]. We previously observed that metabolic rewiring toward mitochondrial respiration drives resistance to 5-fluorouracil (FU) in FU-resistant CRC cells [52] and to platinum in ovarian carcinoma cells upon TRAP1 downregulation [14]. More recent observations suggest that metabolic remodeling toward glycolysis favors resistance to EGFR inhibitors in EGFR-mutated lung carcinoma [38]. As suggested/investigated by other groups, metabolic pathways represent novel molecular targets to counteract drug resistance and cancer progression. In such a view, TRAP1 protein network deserves to be studied as predictive biomarker of poor response to EGFR monoclonals in RAS-wild-type human CRCs and novel putative TRAP1 inhibitors [9,53] warrant to be tested to boost the activity of EGFR monoclonals in human CRCs with predominant/preferential Warburg metabolism.

5. Conclusions

This study provides the proof of concept that TRAP1 is a determinant of metabolic rewiring in human CRCs by the modulation of PFK1 activity/stability and favors resistance to EGFR inhibitors through the regulation of glycolytic metabolism.

Acknowledgements

This work was supported by PRA 2018 grant from the University of Foggia and Ricerca Corrente from the Italian Ministry of Health; POR CAMPANIA FESR 2014/2020 [project “SATIN” (Sviluppo di Approcci Terapeutici INnovativi per patologie neoplastiche resistenti ai trattamenti)]

Conflict of interest

The authors declare no conflict of interest.

Author contributions

FM, ML, and FE involved in study concept and design. VC, DSW, CP, RS, GL, VLB, MP, FC, AP, GS, and NC contributed to acquisition of data. FM, ML, FE, NC, and GS analyzed and interpreted the data, FM, ML, and FE involved in critical revision of
the manuscript; FM, ML, and FE supervised the study.

References
1. Vander Heiden MG & De Berardinis RJ (2017) Understanding the intersections between metabolism and cancer biology. Cell 168, 657–669.
2. Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646–674.
3. Newsholme EA, Crabtree B & Ardawi MS (1985) The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep 5, 393–400.
4. Rinaldi L, Delle Donne R, Borzacchiello D, Insabato L & Feliciello A (2018) The role of compartmentalized signaling pathways in the control of mitochondrial activities in cancer cells. Biochim Biophys Acta Rev Cancer 1869, 293–302.
5. Matassa DS, Agliarulo I, Avolio R, Landriscina M & Esposito F (2018) TRAP1 regulation of cancer metabolism: dual role as oncogene or tumor suppressor. Genes 9, E195.
6. Yu L, Lu M, Jia D, Ma J, Ben-Jacob E, Levine H, Kaipparrettu BA & Onuchic JN (2017) Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation. Cancer Res 77, 1564–1574.
7. Pavlova NN & Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23, 27–47.
8. Pirkkala L & Sistonen L (2006) Heat shock proteins (hsps): structure, function and genetics. In Encyclopedia Life Sciences, pp. 1–7. John Wiley & Sons Ltd, Chichester.
9. Lettini G, Maddalena F, Sisinni L, Condelli V, Matassa DS, Costi MP, Simoni D, Esposito F & Landriscina M (2017) TRAP1: a viable therapeutic target for future cancer treatments? Expert Opin Ther Targets 21, 805–815.
10. Amoroso MR, Matassa DS, Agliarulo I, Avolio R, Maddalena F, Condelli V, Landriscina M & Esposito F (2017) Stress-adaptive response in ovarian cancer drug resistance: role of TRAP1 in oxidative metabolism-driven inflammation. Adv Protein Chem Struct Biol 108, 163–198.
11. Lettini G, Sisinni L, Condelli V, Matassa DS, Simeon V, Maddalena F, Gemi M, Lopes E, Vita G, Del Vecchio L et al. (2016) TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma. Cell Death Differ 23, 1792–1803.
12. Condelli V, Maddalena F, Sisinni L, Lettini G, Matassa DS, Piscazzi A, Pulladino G, Amoroso MR, Esposito F & Landriscina M (2015) Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma. Oncotarget 6, 22298–22309.
13. Matassa DS, Agliarulo I, Amoroso MR, Maddalena F, Sepe L, Ferrari MC, Sagari V, D’Amico S, Lorenzi F, Paolella G et al. (2014) TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: relevance in human colorectal tumors. Mol Oncol 8, 1482–1494.
14. Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I et al. (2016) Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ 23, 1542–1554.
15. Sciacovelli M, Guzzo G, Morelo V, Frezza C, Zheng L, Namini N, Calabrese F, Laudiero G, Esposito F, Landriscina M et al. (2013) The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab 17, 988–999.
16. Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Varholomaiou E, Tatokoro M, Beeke K, Miyajima N et al. (2013) Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci USA 110, 1604–1612.
17. Caimo MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O’Connell M, Jernigan D, Fatatis A et al. (2013) Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest 123, 2907–2920.
18. Maddalena F, Simeon V, Vita G, Bochicchio A, Possidente L, Sisinni L, Lettini G, Condelli V, Matassa DS, Li Bergolis V et al. (2017) TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. Oncotarget 8, 21229–21240.
19. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, Fersini A, Ambrosi A, Neri V, Esposito F, Landriscina M et al. (2009) TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptosis in human colorectal carcinoma cells. Cancer Lett 279, 39–46.
20. Landriscina M, Lauberio G, Maddalena F, Amoroso MR, Piscazzi A, Cozzolino F, Monti M, Garbi C, Fersini A, Pucci P et al. (2010) Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res 70, 6577–6586.
21. Doyle VJ & Bateman AC (2012) Colorectal cancer staging using TNM 7: is it time to use this new staging system? J Clin Pathol 65, 372–374.
22. Giorgetti A, Sorace O, Pisani P, Salvadori PA & Mariani G (2000) Accuracy of qualitative and
semiquantitative analysis of $^{18}$F-FDG positron emission tomography scans in the evaluation of primary and metastatic lesions. *Clin Positron Imaging* **3**, 182.

23 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT *et al.* (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* **92**, 205–216.

24 Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polischuk RS, Maddalena F, Piscazzi A, Paladino S, Sarnataro D, Garbi C *et al.* (2012) TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. *Cell Death Differ* **19**, 592–604.

25 Condelli V, Piscazzi A, Sisinni L, Matassa DS, Maddalena F, Lettini G, Simeon V, Paladino G, Amoroso MR, Trino S *et al.* (2014) TRAP1 is involved in BRF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. *Cancer Res* **74**, 6693–6704.

26 Ruopp MD, Perkins NJ, Whitcomb BW & Schisterman EF (2008) Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom J* **50**, 419–430.

27 Maddalena F, Lettini G, Gallicchio R, Sisinni L, Simeon V, Nardelli A, Venetucci AA, Storto G & Landriscina M (2015) Evaluation of glucose uptake in normal and cancer cell lines by positron emission tomography. *Mol Imaging* **14**, 490–498.

28 Sisinni L, Maddalena F, Condelli V, Pannone G, Simeon V, Li Bergolis V, Lopes E, Piscazzi A, Matassa DS, Mazzoccoli C *et al.* (2017) TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination. *J Pathol* **243**, 123–134.

29 Delgado-Goni T, Minitios MF, Wantuch S, Parkes HG, Marais R, Workman P, Leach MO & Beloueche-Babari M (2016) The BRAF inhibitor Vemurafenib activates mitochondrial metabolism and inhibits hyperpolarized pyruvate-lactate exchange in BRAF-mutant human melanoma cells. *Mol Cancer Ther* **15**, 2987–2999.

30 Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM *et al.* (2014) Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. *Cancer Discov* **4**, 423–433.

31 Berg JM, Tymoczko JL & Stryer L (2002) The glycolytic pathway is tightly controlled, In *Biochemistry* Section 16.2 (Freeman WH, ed), pp. 668–676. 5th edn. W H Freeman, New York, NY.

32 Matassa DS, Amoroso MR, Agliarulo I, Maddalena F, Sisinni L, Paladino S, Romano S, Romano MF, Sagar V, Loreni F *et al.* (2013) Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1. *Cell Death Dis* **4**, e851.

33 Chen KY, Liu X, Bu P, Lin CS, Rakhlin N, Locasale JW & Shen X (2014) A metabolic signature of colon cancer initiating cells. *Conf Proc IEEE Eng Med Biol Soc* **2014**, 4759–4762.

34 Iaffaldano L, Nardelli C, D’Alessio F, D’Argenio V, Nunziato M, Mauriello L, Procaccini C, Maruotti GM, Martinelli P, Matarese G *et al.* (2018) Altered bioenergetic profile in umbilical cord and amniotic mesenchymal stem cells from newborns of obese women. *Stem Cells Dev* **27**, 199–206.

35 Fan F, Bellister S, Lu J, Ye X, Boulbes DR, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L *et al.* (2015) The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. *Br J Cancer* **112**, 539–546.

36 Yalcin A, Teleng S, Clem B & Chesney J (2009) Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer. *Exp Mol Pathol* **86**, 174–179.

37 Williams NC & O’Neill LAJ (2018) A Role for the Krebs cycle intermediate citrate in metabolic reprogramming in innate immunity and inflammation. *Front Immunol* **9**, 141.

38 Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D & Isella C (2018) Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. *Cell Metab* **28**, 848–865.

39 Akerfelt M, Morimoto RI & Sistonen L (2010) Heat shock factors: integrators of cell stress, development and lifespan. *Nat Rev Mol Cell Biol* **11**, 545–555.

40 Bagatell R & Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. *Mol Cancer Ther* **3**, 1021–1030.

41 Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J & Michiels C (1999) Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. *FEBS Lett* **460**, 251–256.

42 Hur E, Kim HH, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee MO & Park H (2002) Reduction of hypoxia induced transcription through the repression of hypoxia-inducible factor1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. *Mol Pharmacol* **62**, 975–982.
43 Jolly C & Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. *J Natl Cancer Inst* **92**, 1564–1572.
44 Luo B & Lee AS (2013) The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. *Oncogene* **32**, 805–818.
45 Whitesell L & Lindquist SL (2005) HSP90 and the chaperoning of cancer. *Nat Rev Cancer* **5**, 761–772.
46 Anderson NM, Mucka P, Kern JG & Feng H (2018) The emerging role and target ability of the TCA cycle in cancer metabolism. *Protein Cell* **9**, 216–237.
47 Diers AR, Broniowska KA, Chang CF & Hogg N (2012) Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. *Biochem J* **444**, 561–571.
48 Iacobazzi V & Infantino V (2014) Citrate-new functions for an old metabolite. *Biol Chem* **395**, 387–399.
49 Lu H, Li X, Luo Z, Liu J & Fan Z (2013) Cetuximab response and molecular chaperones in oncogenesis and unfolded protein cell death. *Oncotarget* **4**, 2289–2293.
50 Schumacher D, Keil M, Yildirim R, Jandrasits C, Schumacher D, Keil M, Yildirim R, Jandrasits C, Borodina T, Amstislavskiy V et al. (2017) Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. *Nat Commun* **8**, 14262.
51 Lehuédé C, Dupuy F, Rabinovitch R, Jones RG & Siegel PM (2016) Metabolic plasticity as a determinant of tumor growth and metastasis. *Cancer Res* **76**, 5201–5208.
52 Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E et al. (2015) 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. *Oncotarget* **6**, 41706–41721.
53 Rondanin R, Lettini G, Oliva P, Baruchello R, Costantini C, Trapella C, Simoni D, Bernardi T, Sisinni L, Pietrafesa M et al. (2018) New TRAP1 and Hsp90 chaperone inhibitors with cationic components: preliminary studies on mitochondrial targeting. *Bioorg Med Chem Lett* **28**, 2289–2293.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** GLUT1 expression correlates with $^{18}$F-FDG uptake in human colorectal carcinomas. Scatter plot representing the statistical correlation between SUV upon $^{18}$F-FDG PET scan and GLUT1 expression in the cohort of 26 human CRCs.

**Fig. S2.** TRAP1 regulates glycolytic metabolism in human CRC cell lines. A. Row data of experiments reported in Figure 2A. TRAP1 immunoblot analysis and corresponding lactate production and OCR data derived from independent siTRAP1 preparations. B. Relative lactate production and 2-DG uptake in transient TRAP1-silenced HCT116 cells. Inserts: TRAP1, GLUT1 and MCT4 immunoblot analysis in transient TRAP1-silenced HCT116 cells. C-D. Relative glucose uptake, lactate production (C) and OCR (D) in TRAP1-silenced HCT116 cells cultured in the presence of high (16.6 mM) or low (5.5 mM) glucose concentration. C. Inserts: TRAP1 immunoblot analysis in TRAP1-silenced HCT116 cells cultured in high or low glucose. The *Mann Whitney* test was used to establish the statistical significance between two group (*p* < 0.05). C. *Anova test*: *p* = 0.0001; Bonferroni post hoc test: siNEG high glucose vs siTRAP1 high glucose, lactate production: *p* < 0.0001, glucose uptake: *p* < 0.0001; siNEG low glucose vs siTRAP1 low glucose, lactate production: *p* < 0.01, glucose uptake: *p* < 0.05).

**Fig. S3.** TRAP1 regulation of glycolysis is independent from BRAF quality control. A-B. Relative 2DG uptake and lactate production in HT29 cells transiently silenced for BRAF and transfected with TRAP1 cDNA (A) or in HCT116 cells transiently silenced for TRAP1 and transfected with the BRAFV600E mutant (B). Inserts: TRAP1 and BRAF immunoblot analysis in HT29 cells silenced for BRAF and transfected with TRAP1 cDNA (A) or in HCT116 cells silenced for TRAP1 and transfected with the BRAFV600E mutant (B). The *Mann Whitney* test was used to establish the statistical significance between two group (*p* < 0.05). A. *Anova test*: *p* = 0.0057; Bonferroni post hoc test: siNEG pmock vs siBRAF pmock, glucose uptake: *p* < 0.001, lactate production: *p* < 0.001; siNEG pmock vs siNEG pTRAP1, glucose uptake: *p* < 0.001, lactate production: *p* < 0.001; siNEG pTRAP1 vs siBRAF pTRAP1: glucose uptake: *p* > 0.05, lactate production: *p* > 0.05. B. *Anova test*: *p* < 0.001; Bonferroni post hoc test: siNEG pmock vs siTRAP1 pmock, glucose uptake: *p* < 0.001, lactate production: *p* < 0.001; siNEG pmock vs siNEG pBRAF, glucose uptake: *p* < 0.001, lactate production: *p* < 0.001; siNEG pBRAF vs siTRAP1 pBRAF: glucose uptake: *p* < 0.001, lactate production: *p* < 0.001.

**Fig. S4.** TRAP1 regulates glycolysis through PKF1. A. PKF1 and TRAP1 immunoblot analysis in shTRAP1 HCT116 cells. B. Relative PKF1 activity in TRAP1-silenced HCT116 cells cultured in the presence of high (16.6 mM) or low (5.5 mM) glucose concentration. Inserts: TRAP1 and PKF1 immunoblot analysis in TRAP1-silenced HCT116 cells cultured in high or low glucose uptake: *p* < 0.0001; Bonferroni post hoc test: siNEG high glucose vs siTRAP1 high glucose, lactate production: *p* < 0.0001, glucose uptake: *p* < 0.0001; siNEG low glucose vs siTRAP1 low glucose, lactate production: *p* < 0.01, glucose uptake: *p* < 0.05).
glucose. C. Real Time PCR analysis of PFK1 mRNA expression in TRAP1-silenced HCT116 cells. Insert: PFK1 and TRAP1 immunoblot analysis in TRAP1-silenced HCT116 cells. D. Relative PFK1 activity and lactate production in shTRAP1 HCT116 cells transfected with TRAP1 cDNA. Insert: PFK1 and TRAP1 immunoblot analysis in shTRAP1 HCT116 cells transfected with TRAP1 cDNA. The Mann Whitney test was used to establish the statistical significance between two group (p<0.05). B. Anova test: p=0.0001; Bonferroni post hoc test: siNEG high glucose vs siTRAP1 high glucose: p<0.0001; siNEG low glucose vs siTRAP1 low glucose: p<0.01. D. Anova test: p=0.001; Bonferroni post hoc test: scramble pmock vs shTRAP1 pmock, lactate production: p<0.001, PFK1 activity: p<0.001; shTRAP1 pmock vs shTRAP1 pTRAP1 lactate production: p<0.01, PFK1 activity: p<0.01.

Fig. S5. ER-associated TRAP1 is responsible for regulation of glycolytic metabolism. A-B. TRAP1 immunoblot analysis in cytosolic, ER and mitochondrial subcellular fractions of TRAP-silenced HCT116 cells (A) and TRAP-silenced HCT116 cells transfected with the Δ1-59 TRAP1-Myc deletion mutant lacking the mitochondrial targeting sequence (B). C. PFK1 activity and lactate production in shTRAP1 HCT116 cells transfected with pMock or the Δ1-59 TRAP1-Myc deletion mutant. Insert. TRAP1 and PFK1 immunoblot analysis in shTRAP1 HCT116 cells transfected with pMock or the Δ1-59 TRAP1-Myc deletion mutant. The Mann Whitney test was used to establish the statistical significance between two group (p<0.05). C. Anova test: p=0.0001; Bonferroni post hoc test: scramble pmock vs shTRAP1 pmock, lactate production: p<0.001, PFK1 activity: p<0.001; scramble pmock vs scramble pΔ1-59TRAP1, lactate production: p<0.0001, PFK1 activity: p<0.0001; scramble pΔ1-59TRAP1 vs shTRAP1 pΔ1-59TRAP1, lactate production: p<0.001, PFK1 activity: p<0.001.

Fig. S6. PFK1 expression is regulated by EGFR signaling. A. PFK1, TRAP1 and MCT4 immunoblot analysis in CaCo2 cells incubated with 100-500 nM cetuximab for 12 h.

Fig. S7. Inhibition of glycolytic metabolism or TRAP1 silencing results in attenuation of spheroid formation. Representative images of spheroid formation assay in RAS-wild type patients-derived CRC spheroids (SA54 cells) cultured in standard medium (A) or incubated with 250 nM cetuximab (B), 10 μM 2DG (C) or 10 μM 3PO (E) for 48 h or silenced for TRAP1 (G) or exposed to the combination of cetuximab and 2DG (D), 3PO (F) or TRAP1 silencing (H).

Fig. S8. High glycolytic metabolism and TRAP1 expression correlate with poor response to cetuximab. A-B. Cell cycle distribution (A) and relative PFK1 activity and lactate production (B) in RAS-wild type CaCo2 cells incubated with 250 nM cetuximab, 10 μM 2DG or 10 μM 3PO for 15 h or silenced for TRAP1 or exposed to the combination of cetuximab and 2DG, 3PO or TRAP1 silencing. Insert: PFK1 and TRAP1 immunoblot analysis in TRAP1-silenced Caco2 cells. The Mann Whitney test was used to establish the statistical significance between two group (p<0.05).

Table S1. Baseline characteristics of colorectal carcinoma patients.

Table S2. TRAP1 and GLUT1 protein levels and 18F-FDG uptake (SUVmax) in human colorectal carcinomas.